ALLMedicine™ Lung Cancer Center

Jun 26th, 2022 - Despite recent advances in treatments and knowledge of biomarkers, patients with metastatic lung cancer have a 5-year survival rate of 5%. Rearranged during transfection (RET) fusions occur in 1% to 2% of lung cancer patients. Pralsetinib has been...

Jun 25th, 2022 - Built environment factors such as air pollution are associated with the risk of respiratory disease, but few studies have carried out profound investigation. We aimed to evaluate the association between the built environment and Chinese women's lu...

Jun 25th, 2022 - Spiritual and existential issues are important factors for oncology patients' well-being. This study aimed to examine the beneficial role of spiritual experience, hope, and meaning in life for life satisfaction in patients diagnosed with breast an...

Jun 25th, 2022 - The aim of this study was to evaluate the cost-effectiveness of durvalumab compared with Best supportive care (BSC) after chemoradiotherapy in patients with stage III non-small cell lung cancer from healthcare system perspective in China. A dynami...

Jun 25th, 2022 - Background IgA vasculitis is the most common form of systemic vasculitis in children but can occur in adults. Inciting antigens include infections, drugs, foods, insect bites, and immunizations. Antibiotics and tumor necrosis factor (TNF) alpha in...

Dec 23rd, 2021 - To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non-small-cell lung cancer (NSCLC). An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, communit...

Dec 14th, 2021 - In Canada, the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC) with rare actionable mutations differs between provinces, territories, and individual centres based on access to molecular testing and funded treatm...

Dec 14th, 2021 - The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment...

Nov 25th, 2021 - By nearly doubling the number of patients eligible for screening, as many as 60,000 US lives may be saved-but concerns may limit acceptance.

Oct 31st, 2021 - Lobectomy is a standard treatment for stage I non-small cell lung cancer, but a significant proportion of patients are considered at high risk for complications, including mortality, after lobectomy and might not be candidates. Identifying who is ...

Jun 24th, 2022 - The purpose of this study is to evaluate the use of investigational agents (MK-4830, MK-5890 and Lenvatinib (MK-7902)) in combination with pembrolizumab and etoposide/platinum chemotherapy for the first-line treatment of participants with extensiv...

Jun 24th, 2022 - Background: Several small molecule poly-(ADP)-ribose polymerase inhibitors (PARPi) have been approved by the FDA for multiple cancers with homologous recombination (HR) deficiencies. Despite their measurable initial benefit, PARPi resistance is a ...

Jun 24th, 2022 - Background: Small cell lung cancer (SCLC) and high-grade neuroendocrine cancers (HGNEC) are aggressive neuroendocrine cancers with poor prognosis. Although responsive to chemotherapy initially, both tumor types relapse quickly and become refractor...

Jun 24th, 2022 - Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to d...

Jun 24th, 2022 - The study is comprised of 2 phases. Phase 1 (dose escalation) includes participants with solid tumors known to express New York esophageal squamous cell carcinoma 1 (NY-ESO-1). Phase 2 (ASP0739 as single agent and in combination with pembrolizumab...

Jun 23rd, 2022 - The US Food and Drug Administration has granted accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for adult and pediatric patients aged 6 years and older with unresectable or metastatic solid tumors with the BRAF V600E mutat...

Jun 22nd, 2022 - Key clinical point : Adagrasib shows favorable clinical efficacy without any new safety signals in patients with previously treated KRASG12C-mutated nonsmall cell lung cancer (NSCLC). Major finding : Among patients with measurable disease at basel.

Jun 22nd, 2022 - Key clinical point : Cemiplimab appears to have the most favorable benefit-risk ratio among the analyzed immune checkpoint inhibitors (ICI) for the treatment of patients with nonsmall cell lung cancer (NSCLC). Major finding : Cemiplimab was associ.

Jun 22nd, 2022 - Key clinical point : A modeling study suggests that the low-dose computed tomography (LDCT) screening of high-risk adults is likely to be cost saving by shifting lung cancer diagnosis to earlier stages. Major finding : LDCT screening would lead to.

Jun 22nd, 2022 - Key clinical point : A meta-analysis suggests that immune checkpoint inhibitors are not very effective against brain metastases (BM) in patients with nonsmall cell lung cancer (NSCLC), except in patients with a programmed cell death-ligand 1 (PD-L.